Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease

JAMA - Journal of the American Medical Association

Volumn 312, Issue 11, 2014, Pages 1114-1121

  Gershon, Andrea S ^a,b,c,d,e   Campitelli, Michael A ^b   Croxford, Ruth ^b   Stanbrook, Matthew B ^b,c,f   To, Teresa ^b,c,d   Upshur, Ross ^b,c   Stephenson, Anne L ^c,g   Stukel, Thérèse A ^b,e  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

AGED; ARTICLE; ASTHMA; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SENSITIVITY ANALYSIS; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; MORTALITY; RISK; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; AGED, 80 AND OVER; ASTHMA; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK;

EID: 84907203469     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.11432     Document Type: Article

References (32)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765-773.
2. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet. 2011;378(9795):991-996.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-2128.
4. Calverley P, Pauwels R, Vestbo J, et al; Trial of Inhaled Steroids and Long-Acting β2 Agonists Study Group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-456.
5. Calverley PM, Anderson JA, Celli B, et al TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
6. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149(6):380-390.
7. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
8. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66(8):699-708.
9. Dore DD, Ziyadeh N, Cai B, Clifford CR, Norman H, Seeger JD. A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims data. BMC Pulm Med. 2014;14:47.
10. Iron K, Zagorski BM, Sykora K, Manuel DG. Living and Dying in Ontario: An Opportunity for Improved Health Information. Toronto, ON: Institute for Clinical Evaluative Sciences; 2008. ICES Investigative Report.
11. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10(2):67-71.
12. Thomas S, Wannell B. Combining cycles of the Canadian Community Health Survey. Health Rep. 2009;20(1):53-58.
13. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. COPD. 2009;6(5):388-394.
14. Gershon A, Croxford R, To T, et al. Comparison of inhaled long-acting β-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study. Ann Intern Med. 2011;154(9):583-592.
15. Finkelstein MM. Ecologic proxies for household income: how well do they work for the analysis of health and health care utilization? Can J Public Health. 2004;95(2):90-94.
16. Reid RJ, MacWilliam L, Verhulst L, Roos N, Atkinson M. Performance of the ACG case-mix system in 2 Canadian provinces. Med Care. 2001;39(1):86-99.
17. D'Agostino RB Jr. Propensity scoremethods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
18. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734-753.
19. Lu SE, Wang MC. Cohort case-control design and analysis for clustered failure-time data. Biometrics. 2002;58(4):764-772.
20. Zhang X, Zhang MJ, Fine J. A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data. Stat Med. 2011;30(16):1933-1951.
21. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying patients with physician-diagnosed asthma in health administrative databases. Can Respir J. 2009;16(6):183-188.
22. Frois C, Wu EQ, Ray S, Colice GL. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther. 2009;31(12):2779-2803.
23. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2014. http://www.goldcopd.org/uploads/users/files/GOLD-Report-2014-Jun11.pdf. Accessed August 25, 2014.
24. Stürmer T, Schneeweiss S, Avorn J, Glynn RJ. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol. 2005;162(3):279-289.
25. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.
26. Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175-1185.
27. Bice TW, Boxerman SB. A quantitative measure of continuity of care. Med Care. 1977;15(4):347-349.
28. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/local/uploads/files/GINA-Report-2014-Aug12.pdf. Accessed August 25, 2014.
29. Global Initiative for Asthma; Global Initiative for Chronic Obstructive Lung Disease. Asthma, COPD, and Asthma-COPD Overlap Syndrome. http://www.ginasthma.org/local/uploads/files/AsthmaCOPDOverlap.pdf. Accessed August 25, 2014.
30. Karner C, Cates CJ. Combination inhaled steroid and long-acting β2-agonist in addition to tiotropium vs tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(3):CD008532.
31. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029-1036.
32. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831-838.